SNGX

Soligenix, Inc.

 
Common Stock SEC Reporting - Current
OTCQB
Verified Company Profile 9/20/2016
Contact Info
  • 29 Emmons Drive
  • Suite C-10
  • Princeton, NJ 08540

Business Description


 
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Sep 30, 2016 10-Q
CIK 0000812796
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Business Status Development Stage Company a/o
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts
Christopher J. Schaber President, CEO
Karen Krumeich CFO
Richard Straube Senior VP, Chief Med. Officer
Oreola Donini Senior VP, Chief Scientific Officer
Company Directors
Christopher J. Schaber Chairman
Keith Brownlie
Marco Brughera
Gregg Lapointe
Robert Rubin
Jerry Zeldis
Company Notes
  • Formerly=DOR BioPharma, Inc. until 9-2009
  • Formerly=Endorex Corp. until 12-01
  • Formerly=ImmunoTherapeutics, Inc. until 9-96
Service Providers
Accounting/Auditing Firm
EisnerAmper LLP
101 West Avenue
P.O. Box 458
Jenkintown, PA, 19046
United States

Legal Counsel
Duane Morris LLP
1540 Broadway
New York, NY, 10036-4086
United States

Investor Relations Firm
Not Available
SNGX Security Details
Share Structure
Market Value1 $11,674,767 a/o Dec 08, 2016
Authorized Shares 10,000,000 a/o Sep 30, 2016
Outstanding Shares 3,766,054 a/o Nov 04, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value Not Available
Shareholders
Shareholders of Record 404 a/o Mar 24, 2016
Short Selling Data
Short Interest 51,077 (9.02%)
Nov 15, 2016
Significant Failures to Deliver No

1Market Value calculated only for respective security